A 'comically competitive' environment is forcing smaller VC investors to rethink their playbooks.
October 18, 2026  |  Log in   |  Read online   |  Manage your subscription  
PitchBook, a Morningstar company
The Weekend Pitch
Presented by Formidium
Sponsored by Formidium
Squeezed at seed, smaller VCs are courting founders who haven’t founded anything yet
jacob-robbins-headshot.jpg
By Jacob Robbins
Technology Reporter
MOSCONE 2

Smaller investors at TechCrunch Disrupt in San Francisco this week described a “comically competitive” environment.

|

Jenna O’Malley/PitchBook

For Danielle London, a principal and investor at venture firm Base10, competition for a deal now starts before a company exists.

“[Companies are] getting funded way earlier and at higher valuations. That means you’re talking to a founder way before the genesis of the business happens,” London said.

It’s already a record year for the earliest stages of fundraising. Investors have funded an estimated 8,625 first-time VC financings in the US through Q3, topping the previous record set in 2021, according to PitchBook data. At the same time, the number of active VCs has been declining for years.

In theory, an explosion of new companies and a narrower pool of firms should mean VCs are spoiled for choice. But in conversations at TechCrunch Disrupt this week, smaller firms described an increasingly competitive environment where they’re struggling to get in the door at all.

US VC first-time financings through Q3 already outnumbers 2021's full-year record

“The broader dealmaking environment has gotten almost comically competitive,” said Rob Biederman, founder and managing partner of Asymmetric Capital Partners. Valuations have become unrecognizable at the earliest stages. The median pre-money valuation for a pre-seed deal in the US has tripled to $12 million from $4 million in 2020.

To compete, smaller VCs are going after founders earlier than ever, from courting academics who never planned to start companies to funding ideas that have yet to become businesses. They’re also rethinking check sizes, ownership and deal terms to win over founders.

Keep reading
A MESSAGE FROM FORMIDIUM
Building an Audit Trail for the AI-Native Fund

At a dinner we hosted in San Francisco with fund leaders and technologists, one question kept coming up: how do I know the AI is actually working? We hear the same question from clients as AI moves beyond answering questions and begins participating in fund operations.

In this article, we take a capital call and follow it through the operating path - from LPA, through retrieval, model reasoning, permissions, calculations and approvals, to fund record. The aim is to show where trust can break, what an operator needs to reconstruct the work, and how we think about that problem as we build ARYA, our AI-native fund administration platform. For managers deciding what AI should take on next, this is our view from inside the stack.

Read more

Formidium 10/18/26 Column image

TRIVIA

Since the pandemic, PE firms have piled into med spas, an area of healthcare with more stable profitability due to up-front payments and recurring procedures. One of the most sought-after services is Botox injections, but the product wasn’t initially designed for cosmetic use. What did the FDA originally approve Botox to treat?

A) Chronic migraines
B) Crossed eyes and uncontrollable blinking
C) Excessive sweating
D) Neck muscle spasms


ICYMI

LMM

Smaller PE managers feel the squeeze as larger funds move down market

The growing influx of capital is making the lower middle market increasingly crowded.

N&A-Michael-Bodley-Weekender-03.01.26_Header Image copy.png

Do GP valuations hold up? Check the secondary market

Some LPs are using secondary-market pricing to assess managers’ reporting, then using it to decide on who to back.

NB_06.28.25_Shi_Weekender_Header Image.png

CVs: If they are trophy assets, why do so few LPs want to roll over?

LPs are choosing to cash out of continuation vehicles, and it is often about the clock, the mandate and the process.


QUOTE/UNQUOTE